体外心肺复苏支持患者的神经功能损伤:临床特征与长期结局
本研究纳入2015年1月至2022年2月本院37例接受静脉-动脉体外膜氧合(VA-ECMO)的成人心脏骤停患者,按有无神经功能损伤分组比较基线、心肺复苏及ECMO相关特征,并通过电话随访收集长期神经功能结局。24例(64.9%)ECPR支持患者发生神经功能损伤。神经功能损伤组28天死亡率(P=0.001)、住院死亡率(P=0.003)、心脏骤停至自主循环恢复中位时间(P=0.029)、无搏动性灌注>12小时比例(P=0.040)及中位ECMO持续时间(P=0.047)更高;无神经功能损伤组中位ICU住院时间(P=0.047)、中位住院时间(P=0.031)更长且成功脱离ECMO更多(P=0.049)。无搏动性灌注>12小时联合IABP支持(OR 14.769;95%CI 1.417~153.889;P=0.024)和血清肌酐水平(OR 1.028;95%CI 1.001~1.056;P=0.043)为神经功能损伤的独立危险因素。神经功能损伤与显著更差的90天生存相关(HR 4.218;95%CI 1.745~10.2;P=0.0014)。
要点
- 37例ECPR支持的成人心脏骤停患者中,24例(64.9%)发生神经功能损伤。
- 神经功能损伤组28天死亡率(P=0.001)和住院死亡率(P=0.003)均显著高于无神经功能损伤组。
- 无搏动性灌注>12小时联合IABP支持是神经功能损伤的独立危险因素(OR 14.769;95%CI 1.417~153.889;P=0.024)。
- 血清肌酐水平是神经功能损伤的独立危险因素(OR 1.028;95%CI 1.001~1.056;P=0.043)。
- 神经功能损伤与显著更差的90天生存相关(HR 4.218;95%CI 1.745~10.2;P=0.0014)。
适用人群与场景
- 2015年1月至2022年2月期间入住本科室的37例接受静脉-动脉体外膜氧合(VA-ECMO)的成人心脏骤停患者。
研究设计与关键结果
- 研究类型为单中心研究,共纳入37例接受ECPR支持的成人心脏骤停患者,按有无神经功能损伤分组比较。
- 24例(64.9%)ECPR支持患者发生神经功能损伤。
- 两组在ECMO前中位年龄(P=0.026)、主动脉内球囊反搏(IABP)支持比例(P=0.011)、连续肾脏替代治疗比例(P=0.025)和中位血清肌酐水平(P=0.012)上存在显著差异。
- 神经功能损伤组28天死亡率(P=0.001)、住院死亡率(P=0.003)、心脏骤停至自主循环恢复中位时间(P=0.029)、无搏动性灌注>12小时患者比例(P=0.040)和中位ECMO持续时间(P=0.047)更高。
- 无神经功能损伤组中位ICU住院时间更长(P=0.047)、中位住院时间更长(P=0.031)且成功脱离ECMO更多(P=0.049)。
- 多因素分析显示,无搏动性灌注>12小时联合IABP支持(OR 14.769;95%CI 1.417~153.889;P=0.024)和血清肌酐水平(OR 1.028;95%CI 1.001~1.056;P=0.043)是神经功能损伤的独立危险因素。
- 神经功能损伤与显著更差的90天生存相关(HR 4.218;95%CI 1.745~10.2;P=0.0014)。
证据类型、等级与局限
- 证据类型:单中心研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 原文未据此给出推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Introduction: The present study aimed to explore the clinical features and long-term outcomes associated with neurologic impairment in patients with cardiac arrest (CA) who received extracorporeal cardiopulmonary resuscitation (ECPR). Methods: A total of 37 adult CA patients who underwent venoarterial extracorporeal membrane oxygenation and were admitted to our department between January 2015 and February 2022 were divided according to neurologic impairment. Baseline and CPR- and ECMO-related characteristics were compared between the two groups. Long-term neurologic outcomes were collected via telephone follow-ups. Results: Twenty-four (64.9%) ECPR-supported patients developed neurologic impairments. The two groups differed significantly in median age (P = 0.026), proportion of intra-aortic balloon pump (IABP) support (P = 0.011), proportion of continuous renal replacement therapy (P = 0.025), and median serum creatinine (Cr) level (P = 0.012) pre-ECMO. The 28-day mortality (P = 0.001), hospital mortality (P = 0.003), median duration from CA to restoration of spontaneous circulation (P = 0.029), proportion of patients with nonpulsatile perfusion (NP) >12 hours (P = 0.040), and median ECMO duration (P = 0.047) were higher in the neurologic impairment group. In contrast, the group without neurologic impairment exhibited a longer median intensive care unit length of stay (P = 0.047), longer median hospital LOS (P = 0.031), and more successful ECMO weaning (P = 0.049). Moreover, NP >12 hours combined with IABP support (odds ratio [OR], 14.769; 95% confidence interval [CI], 1.417~153.889; P = 0.024) and serum Cr level (OR, 1.028; 95% CI, 1.001~1.056; P = 0.043) were independent risk factors for neurologic impairment. Furthermore, neurologic impairment was associated with significantly worse 90-day survival (hazards ratio, 4.218; 95% CI, 1.745~10.2; P = 0.0014). Conclusions: The incidence of neurologic impairment was higher in patients who received ECPR and was closely related to 28-day mortality and discharge survival. NP >12 hours combined with IABP support and serum Cr levels were independent risk factors for neurologic impairments in ECPR-supported patients. Neurologic impairment significantly adversely affected the long-term outcomes of ECPR-supported patients after discharge.
参考来源
- Shi X, Zhang L, Zeng X, et al. NEUROLOGIC IMPAIRMENT IN PATIENTS WITH EXTRACORPOREAL CARDIOPULMONARY RESUSCITATION SUPPORT: CLINICAL FEATURES AND LONG-TERM OUTCOMES. Shock. 2022. PMID: 36703277. doi:10.1097/SHK.0000000000002041
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。